Diagnosis and Treatment of Urologic Oncology

Dear Colleagues,

Urologic oncology encompasses the study, diagnosis, and treatment of cancers affecting the urinary system and male reproductive organs, including prostate, bladder, kidney, and testicular cancers. These malignancies represent a significant portion of global cancer incidence, with prostate cancer being the second most common cancer in men worldwide. The evolution of urologic oncology has seen significant advancements in both diagnostic tools, such as imaging and biomarkers, and treatment modalities, including surgery, radiation therapy, chemotherapy, and, more recently, immunotherapy and targeted therapies. Over the past few decades, research has moved from focusing solely on survival to also considering quality of life, leading to the development of less invasive treatments and personalized medicine approaches. This Special Issue will present a comprehensive collection of the latest research and reviews on the diagnosis and treatment of urologic oncology. It will cover a broad spectrum of advancements in this field, from early detection and screening strategies to novel therapeutic approaches and multidisciplinary management of advanced and metastatic urologic cancers. This Special Issue’s scope includes, but is not limited to, cutting-edge diagnostic technologies, innovative surgical techniques, targeted therapies, the role of precision medicine, and the impacts of these advancements on patient outcomes. We are soliciting a wide range of papers that contribute to our understanding and the advancement of urologic oncology. These include, but are not limited to, original research articles, review articles, and technical notes with descriptions of new surgical techniques or innovations in diagnostic technologies.

This Special Issue will serve as a valuable resource for clinicians, researchers, and healthcare professionals involved in the diagnosis and treatment of urologic cancers, as well as for policymakers and educators in the field of urological oncology.

Dr. Juan Gómez Rivas
Dr. Jesús Moreno-Sierra
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• bladder cancer
• kidney cancer
• personalized medicine
• prostate cancer
• robotic surgery
• targeted therapy
• testicular cancer